SUNPHARMA

Balances US Generics Pressure with Specialty Expansion

is working to stabilize its US generics business, which has faced price erosion and competitive pressure, by improving manufacturing compliance and resuming new product launches. In Q3FY26, US generics sales rose 0.6% YoY to $477 million, while specialty and innovative therapies contributed 27.5% of consolidated sales. The company is also preparing for the India launch of generic semaglutide, a key near-term growth catalyst. US Generics and Compliance Strategy - US generics portfolio under pressure due to pricing and competition. - Q3FY26 US generics sales: $477 million, up 0.6% YoY. - Focused on regulatory improvements and manufacturing compliance at key facilities. - Plans to ramp up new launches to regain momentum. Specialty and Innovation-Led Growth - Specialty and innovative therapies now form 27.5% of total sales. - Key US launches: - UNLOXCYT for advanced cutaneous squamous cell carcinoma. - LEQSELVI for severe alopecia areata. - Continued investment in R&D across generics and innovative medicines. India Business and Semaglutide Opportunity - Preparing for Day 1 launch of generic semaglutide post patent expiry. - Regulatory approvals secured for type-2 diabetes and chronic weight management indications. - Expected to be a major growth driver in India’s chronic care segment. Strategic Outlook and M&A - Exploring selective acquisitions to strengthen innovation pipeline. - Focus remains on balancing generics stability with specialty expansion. - Management confident that US generics pressure will ease as compliance and launches improve.